These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26399468)

  • 1. The FDA's new clothes.
    Light DW; Lexchin J
    BMJ; 2015 Sep; 351():h4897. PubMed ID: 26399468
    [No Abstract]   [Full Text] [Related]  

  • 2. US FDA's safety monitoring of drugs with expedited approval.
    Furlow B
    Lancet Oncol; 2016 Mar; 17(3):281. PubMed ID: 26831290
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues.
    Miller HI
    Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation.
    Downing NS; Krumholz HM; Ross JS; Shah ND
    Nat Rev Drug Discov; 2015 Nov; 14(11):740-1. PubMed ID: 26435528
    [No Abstract]   [Full Text] [Related]  

  • 5. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
    Wang B; Kesselheim AS
    BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative.
    Brown JD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1050. PubMed ID: 32715968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
    Chambers JD; Thorat T; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2017 Aug; 36(8):1408-1415. PubMed ID: 28784733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
    Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
    PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On FDA's future.
    Samuel FE
    Am Pharm; 1991 Aug; NS31(8):35, 37. PubMed ID: 1927896
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA: friend or foe?
    Lewis TS
    Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's Dunham delves into drug issues.
    Dunham B; Kahler SC
    J Am Vet Med Assoc; 2014 Apr; 244(7):762-3. PubMed ID: 24783315
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
    Sasinowski FJ; Varond AJ
    Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.